AR030704A1 - Enantiomero de quinazolina 1,2-anillado, composiciones farmaceuticas que lo comprenden, procedimiento para preparar dichas composiciones, uso de dicho compuesto en la manufactura de medicamentos para inhibir el desarrollo de tumores y procedimiento para la preparacion de dicho compuesto - Google Patents
Enantiomero de quinazolina 1,2-anillado, composiciones farmaceuticas que lo comprenden, procedimiento para preparar dichas composiciones, uso de dicho compuesto en la manufactura de medicamentos para inhibir el desarrollo de tumores y procedimiento para la preparacion de dicho compuestoInfo
- Publication number
- AR030704A1 AR030704A1 ARP010102954A ARP010102954A AR030704A1 AR 030704 A1 AR030704 A1 AR 030704A1 AR P010102954 A ARP010102954 A AR P010102954A AR P010102954 A ARP010102954 A AR P010102954A AR 030704 A1 AR030704 A1 AR 030704A1
- Authority
- AR
- Argentina
- Prior art keywords
- procedure
- compositions
- tumors
- inhibit
- manufacture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract 2
- -1 1-methyl-1H-imidazol-5-yl Chemical group 0.000 abstract 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003246 quinazolines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00202181 | 2000-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030704A1 true AR030704A1 (es) | 2003-09-03 |
Family
ID=8171675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102954A AR030704A1 (es) | 2000-06-22 | 2001-06-21 | Enantiomero de quinazolina 1,2-anillado, composiciones farmaceuticas que lo comprenden, procedimiento para preparar dichas composiciones, uso de dicho compuesto en la manufactura de medicamentos para inhibir el desarrollo de tumores y procedimiento para la preparacion de dicho compuesto |
Country Status (33)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018135A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase |
| ATE336496T1 (de) | 2002-04-15 | 2006-09-15 | Janssen Pharmaceutica Nv | Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen |
| US20050003422A1 (en) | 2003-07-01 | 2005-01-06 | Mitch Reponi | Methods for assessing and treating cancer |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| EP3226973A4 (en) * | 2014-12-04 | 2018-05-30 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10835496B2 (en) | 2015-04-21 | 2020-11-17 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| EA201890512A1 (ru) | 2015-08-17 | 2018-09-28 | Кура Онколоджи, Инк. | Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы |
| RS61745B1 (sr) | 2016-11-03 | 2021-05-31 | Kura Oncology Inc | Inhibitori farneziltransferaze za upotrebu u tretiranju kancera |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1519765A (en) * | 1974-09-05 | 1978-08-02 | Ici Ltd | Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes |
| US4141979A (en) * | 1976-12-23 | 1979-02-27 | Pfizer Inc. | Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents |
| GB9513577D0 (en) * | 1995-07-04 | 1995-09-06 | Brotherwood Rodney J | Improvements in passenger carrying vehicles |
| TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| EE03484B1 (et) * | 1995-12-08 | 2001-08-15 | Janssen Pharmaceutica N.V. | Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine |
| AU715658B2 (en) | 1996-04-03 | 2000-02-10 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| BR9809398A (pt) * | 1997-04-25 | 2000-06-13 | Janssen Pharmaceutica Nv | Quinazolinonas que inibem a farnesil transferase |
| ATE222104T1 (de) | 1997-06-02 | 2002-08-15 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen |
| US6545020B1 (en) * | 1998-07-06 | 2003-04-08 | Janssen Pharmaceutica, N.V. | Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties |
| HRP20000904A2 (en) | 1998-07-06 | 2001-12-31 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors for treating arthropathies |
| TR200101343T2 (tr) * | 1998-08-27 | 2001-09-21 | Pfizer Products Inc. | Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri |
| ATE289602T1 (de) * | 1998-08-27 | 2005-03-15 | Pfizer Prod Inc | Quinolin-2-on-derivate verwendbar als antikrebsmittel |
| BR9916827A (pt) * | 1998-12-23 | 2001-10-16 | Janssen Pharmaceutica Nv | Derivados de quinolina 1,2-anelados |
| US6462201B1 (en) * | 1998-12-29 | 2002-10-08 | Isp Investments Inc. | Process for the production of N-vinyl-2-pyrrolidone by vinylation |
| KR20010102073A (ko) * | 1999-02-11 | 2001-11-15 | 실버스타인 아써 에이. | 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체 |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| US6838467B2 (en) * | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
| WO2002024686A2 (en) | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| JP4974439B2 (ja) | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体 |
-
2001
- 2001-05-29 JO JO200183A patent/JO2361B1/en active
- 2001-06-13 EP EP01938263A patent/EP1296984B1/en not_active Expired - Lifetime
- 2001-06-13 BR BRPI0111743-2 patent/BRPI0111743B8/pt not_active IP Right Cessation
- 2001-06-13 AU AU6396201A patent/AU6396201A/xx active Pending
- 2001-06-13 US US10/312,301 patent/US20030114471A1/en not_active Abandoned
- 2001-06-13 AU AU2001263962A patent/AU2001263962B2/en not_active Expired
- 2001-06-13 ES ES01938263T patent/ES2241830T3/es not_active Expired - Lifetime
- 2001-06-13 WO PCT/EP2001/006747 patent/WO2001098302A1/en not_active Ceased
- 2001-06-13 EE EEP200200695A patent/EE04966B1/xx unknown
- 2001-06-13 IL IL15356001A patent/IL153560A0/xx unknown
- 2001-06-13 SK SK50-2003A patent/SK285699B6/sk not_active IP Right Cessation
- 2001-06-13 HU HU0300872A patent/HU229095B1/hu unknown
- 2001-06-13 DE DE60110592T patent/DE60110592T2/de not_active Expired - Lifetime
- 2001-06-13 KR KR1020077026608A patent/KR100846370B1/ko not_active Expired - Lifetime
- 2001-06-13 JP JP2002504258A patent/JP4919575B2/ja not_active Expired - Lifetime
- 2001-06-13 NZ NZ522481A patent/NZ522481A/en not_active IP Right Cessation
- 2001-06-13 KR KR1020027014678A patent/KR100831940B1/ko not_active Expired - Lifetime
- 2001-06-13 CN CNB018113788A patent/CN1207296C/zh not_active Expired - Lifetime
- 2001-06-13 HR HR20020989A patent/HRP20020989B1/xx not_active IP Right Cessation
- 2001-06-13 MX MXPA02012845A patent/MXPA02012845A/es active IP Right Grant
- 2001-06-13 AT AT01938263T patent/ATE294804T1/de active
- 2001-06-13 EA EA200300048A patent/EA005065B1/ru not_active IP Right Cessation
- 2001-06-13 CA CA002410232A patent/CA2410232C/en not_active Expired - Lifetime
- 2001-06-13 CZ CZ2003114A patent/CZ295278B6/cs not_active IP Right Cessation
- 2001-06-13 PL PL358918A patent/PL209521B1/pl unknown
- 2001-06-13 UA UA20021210152A patent/UA73572C2/uk unknown
- 2001-06-14 PA PA20018519501A patent/PA8519501A1/es unknown
- 2001-06-20 MY MYPI20012896A patent/MY127734A/en unknown
- 2001-06-20 EG EG20010660A patent/EG24180A/xx active
- 2001-06-21 AR ARP010102954A patent/AR030704A1/es not_active Application Discontinuation
- 2001-09-10 SA SA01220349A patent/SA01220349B1/ar unknown
-
2002
- 2002-10-25 IS IS6590A patent/IS2596B/is unknown
- 2002-11-25 BG BG107310A patent/BG65894B1/bg unknown
- 2002-12-16 NO NO20026032A patent/NO324494B1/no not_active IP Right Cessation
- 2002-12-19 IL IL153560A patent/IL153560A/en not_active IP Right Cessation
- 2002-12-19 ZA ZA200210305A patent/ZA200210305B/en unknown
-
2006
- 2006-09-20 AU AU2006220405A patent/AU2006220405B2/en not_active Expired
-
2007
- 2007-01-31 US US11/669,587 patent/US8329714B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/926,741 patent/US8318753B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
| DOP2004000949A (es) | Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos | |
| TNSN06226A1 (en) | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| IL182893A0 (en) | PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| CL2008001364A1 (es) | Uso de compuestos derivados de imidazol(1,2-b) piridazina y pirazolo(1,5-a) pirimidina inhibidores de tirosina quinasa pi-para tratar tumor benigno o maligno, entre otros; compuestos dereivados de imidazol(1,2-b)piridazina y pirazolo(1,5-a)pirimidina; composiciones farmaceuticas; y metodo de preparacion de compuestos. | |
| DK1326613T4 (da) | Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering | |
| MX2007005644A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa. | |
| BR0215312A (pt) | Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
| AR033671A1 (es) | Composicion farmaceutica acuosa del tipo de gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento | |
| BR0009847A (pt) | Kit de partes, método de preparação de um kit de partes, formulação farmacêutica, método de tratamento de uma condição na qual inibição de trombina é requerida ou desejada, e, uso de um inibidor de trombina, ou de um derivado farmaceuticamente aceitável do mesmo | |
| BR0112619A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, métodos para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e de distúrbios no sistema nervoso central e/ou de bexiga hiperativa ou vasospasmo ou para o controle do crescimento de tumores | |
| EE200200695A (et) | (-)-5-(3-klorofenüül)-alfa-(4-klorofenüül)-alfa-(1-metüül-1H-imidasool-5-üül)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks | |
| BRPI0513287A (pt) | derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica | |
| AR024411A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo[2.2.2]oct-3-ilamina y sus composiciones farmaceuticas. | |
| ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
| MXPA05012826A (es) | Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen. | |
| ES2263835T3 (es) | Terapia combinada contra tumores que comprende derivados de distamicina acriloil sustituidos e inhibidores proteina quinasa (serina/treonina quinasa). | |
| PE20260438A1 (es) | Composiciones farmaceuticas | |
| ATE308995T1 (de) | Pharmazeutische zusammensetzung und verfahren zur behandlung von retroviralen infektionen | |
| UY28409A1 (es) | Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden | |
| TH59553A (th) | องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วย 1,2-แอนเนเลเทด ควิโนลีน อิแนนชิโอเมอร์ซึ่งมีฤทธิ์ยับยั้งฟาร์เนซิลทรานส์เฟอเรส | |
| TH55580A (th) | สารประกอบแลคแทม |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |